BioDirection Obtains Exclusive Technology Rights from Nanosys, Inc.

BioDirection Obtains Exclusive Technology Rights from Nanosys, Inc.

March 13, 2012

Tucson, AZ – (BUSINESS WIRE) – BioDirection, Inc., a developer of point-of-care brain injury screening devices to separate minor head injuries from mild traumatic head injury, announced that it has signed an exclusive license agreement with Nanosys, Inc., an advanced materials architect, for an extensive portfolio of Harvard University generated nanowire patents and patent applications.

The licensing agreement grants BioDirection exclusive, worldwide rights for the use of nanowires for biosensor applications in the field of brain injury detection and monitoring. The expansive intellectual property portfolio, invented by Dr. Charles Lieber, a pioneer in the field of nanowire technology, includes 11 issued U.S. Patents, 5 pending applications and broad filing in key foreign jurisdictions.

"The quality and depth of the licensed intellectual portfolio will solidify our proprietary position in the field of brain injury management," stated Brian McGlynn, President & CEO of BioDirection. "We expect to launch TbitTM, our initial product, during the first half of 2013 following receipt of all regulatory clearances."

The small handheld device is based on the latest advances in dual bio-marker and nanowire technology. A single drop of blood taken within minutes following the suspected injury will generate a test result in approximately 60 seconds.

Mr. McGlynn went on to say, "Today, diagnosis is symptom based and current post-injury examinations are frequently inconclusive – symptoms may not appear for weeks or months. When injury occurs, early identification and medical intervention are top priorities. This urgent need inspired the creation of Tbit."

About BioDirection

BioDirection, Inc. is a privately-held medical device company focused on the design, development and commercialization of easy-to-use, low cost and portable point-of-care biomarker devices for screening and monitoring of brain injury. The company's strategy is to blend proven technologies into innovative diagnostic tools to address critical market needs. For more information, visit http://www.biodirection.com.

Nanosys, Inc. is an advanced material architect, harnessing the fundamental properties of inorganic materials into process ready systems that can integrate into existing manufacturing to produce vastly superior products in lighting, electronic displays and energy storage. For more information, visit www.nanosysinc.com.

Contacts

BioDirection, Inc.
James A. Wylie, 203-240-1319
Executive Chairman
jwylie@biodirection.com

or

Planet Communications
Deanne Eagle, 917-837-5866
deanneeagle@gmail.com

BioDirection is always searching for new opportunities. Contact us today with any questions or inquiries.